Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $44.10 USD
Change Today -0.91 / -2.02%
Volume 596.2K
XON On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

intrexon corp (XON) Snapshot

Open
$44.84
Previous Close
$45.01
Day High
$45.96
Day Low
$44.03
52 Week High
03/4/15 - $50.98
52 Week Low
05/9/14 - $13.13
Market Cap
4.6B
Average Volume 10 Days
954.3K
EPS TTM
$-1.08
Shares Outstanding
105.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTREXON CORP (XON)

intrexon corp (XON) Related Businessweek News

View More BusinessWeek News

intrexon corp (XON) Details

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; AquaBounty Technologies, Inc.; S & I Ophthalmic, LLC; Biological & Popular Culture, Inc.; OvaXon, LLC; Intrexon Energy Partners, LLC; and Persea Bio, LLC; and strategic collaboration and licensing agreement with Merck Serono S.A. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

480 Employees
Last Reported Date: 03/2/15
Founded in 1998

intrexon corp (XON) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: --
Chief Operating Officer
Total Annual Compensation: $2.1M
Senior Vice President of Energy Sector
Total Annual Compensation: $341.0K
Compensation as of Fiscal Year 2013.

intrexon corp (XON) Key Developments

ZIOPHARM Oncology, Inc. and Intrexon Corporation Enters into Worldwide License and Collaboration Agreement with ARES Trading S.A

On March 27, 2015, ZIOPHARM Oncology, Inc. and Intrexon Corporation entered into a worldwide License and Collaboration Agreement or the Ares Trading Agreement with ARES Trading S.A. through which the parties established a collaboration for the research and development and commercialization of Products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. The Ares Trading Agreement provides for the establishment of committees composed of Ares Trading and Intrexon representatives that will govern activities in, among others, the areas of project establishment, research plans and intellectual property. The Ares Trading Agreement grants Ares Trading an exclusive, worldwide, royalty-bearing, sub-licensable license under the company's and Intrexon's patents, know-how and proprietary platform of research tools and technology necessary for the company and Intrexon to perform their tasks directed towards the design, identification, culturing, and/or production of genetically modified cells to generate and test Chimeric Antigen Receptor T-Cell Products solely for the development, regulatory approval and commercialization of Products containing such Chimeric Antigen Receptor T-Cell Products pursuant to the licenses granted in clauses (b) and (c) of this paragraph; develop and commercialize Products in the Field, worldwide, provided that such Products are not Out-of-Scope Products where Ares Trading has not exercised its Option; and commercialize the chimeric antigen receptor for Products. Ares Trading will pay an upfront fee of $115.0 million to Intrexon as consideration for entry into the Ares Trading Agreement. Intrexon will pay 50% of the fee to the company in accordance with the ECP Amendment. Ares Trading will, pursuant to the terms of the Ares Trading Agreement, pay Intrexon certain fees for the research and development activities related to the products.

Intrexon Corporation Signs Cooperative Research and Development Agreement with the National Cancer Institute for RheoSwitch® Controlled IL-12 Cancer Therapies Using T Cell Receptors (TCR) Derived from Peripheral Blood

Intrexon Corporation announced that Intrexon has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, for the development of adoptive T cell therapies utilizing the RheoSwitch Therapeutic System® (RTS®) platform for the treatment of solid tumor malignancies. The principal goal of the CRADA is to develop and evaluate improved adoptive cell transfer-based immunotherapies (ACT) using NCI proprietary methods for the identification of autologous peripheral blood lymphocytes (PBL) possessing naturally occurring anti-tumor activity combined with Intrexon's RTS® gene switch for introducing spatially and temporally controlled interleukin-12 (IL-12) expression. RTS® technology enables transcriptional regulation of a wide variety of therapeutic genes upon dosing of an oral activator ligand veledimex, including in vivo modulation of IL-12 gene expression with a broad dynamic range. As the first gene switch employed in the clinic to enable dose-dependent cytokine expression and offer the ability to administer or withdraw veledimex for continued treatment cycles, the RheoSwitch® platform provides the opportunity to tailor solutions for patient-specific therapeutic effects. Intrexon will genetically modify PBL using vectors that encode IL-12 under RTS® inducible control. Lead anti-tumor ACT/PBL/IL-12 cell therapy candidates will then be clinically evaluated by NCI in patients with metastatic cancer.

Merck Serono S.A. Enters into Strategic Collaboration and Licensing Agreement with Intrexon Corporation

Merck Serono S.A. entered into an strategic collaboration and licensing agreement with Intrexon Corporation to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. The agreement provides Merck Serono exclusive access to Intrexon's proprietary and complementary suite of technologies to engineer T-cells with optimized and inducible gene expression. Intrexon will be responsible for all platform and product developments until investigational new drug (IND) filing. Merck will nominate targets of interest for which CAR-T products will be developed. Merck will also lead the IND filing and pre-IND interactions, clinical development and commercialization. In addition, Intrexon has the opportunity to explore targets independently, granting Merck opt-in rights during clinical development. Under the terms of the agreement, Intrexon will receive an upfront payment of $115 million. For the first two targets of interest selected by Merck Serono, Intrexon will receive research funding and is eligible to receive up to $826 million development, regulatory and commercial milestones, as well as tiered royalties on product sales. In addition, Intrexon is also eligible to receive further payments upon achievement of certain technology development milestones.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XON:US $44.10 USD -0.91

XON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $180.08 USD -4.50
Photon Technology International Inc $0.0001 USD 0.00
MorphoSys AG €65.71 EUR +0.457
XOMA Corp $3.60 USD -0.02
View Industry Companies
 

Industry Analysis

XON

Industry Average

Valuation XON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 61.6x
Price/Book 11.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 62.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTREXON CORP, please visit www.dna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.